{
    "clinical_study": {
        "@rank": "63630", 
        "arm_group": [
            {
                "arm_group_label": "JNJ-42396302", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours."
            }, 
            {
                "arm_group_label": "JNJ-42692507", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours."
            }, 
            {
                "arm_group_label": "JNJ-53773187", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to investigate the pharmacokinetics (what the body does to the\n      medication) of JNJ-42396302, JNJ-53773187 and JNJ-42692507 after administration of a single\n      oral dose of 100 micrograms under fasted conditions in healthy male participants."
        }, 
        "brief_title": "A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This is a phase I, open-label (all people know the identity of the intervention) and\n      parallel-group (each group of patients will be treated at the same time), randomized (the\n      study medication is assigned by chance) study in healthy male participants, to investigate\n      the pharmacokinetics of a single oral dose of 100 micrograms of JNJ-42396302, JNJ-53773187\n      or JNJ-42692507. The study consists of 3 phases, ie, screening phase (21 days prior to first\n      dose of study medication), a treatment phase, and a follow up phase. In the treatment phase,\n      participants will be   divided into 3 treatment groups with 6 participants each, to receive\n      a single dose of 100 micrograms of JNJ-42396302, JNJ-53773187 or JNJ-42692507 following an\n      overnight fast of at least 10 hours. Safety evaluations for adverse events, clinical\n      laboratory tests, physical examination, vital signs and electrocardiogram will be monitored\n      throughout the study. The total duration of the study will be approximately 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant should be healthy male on the basis of physical examination, medical\n             history, vital signs, electrocardiogram, the results of blood biochemistry and\n             hematology tests and a urinalysis\n\n          -  Participant must have a Body Mass Index of 18.5 to 30.0 kg/m2\n\n          -  Have a blood pressure between 90 and 140 mm Hg systolic, inclusive, and no higher\n             than 90 mm Hg diastolic\n\n          -  Agrees to protocol-defined use of effective contraception\n\n        Exclusion Criteria:\n\n          -  A positive human immunodeficiency virus-type 1 or type 2 test and Hepatitis A, B or C\n             infection at screening or admission\n\n          -  Participant with abnormal physical, vital or laboratory values\n\n          -  Currently active cardiovascular, bronchospastic respiratory disease, dyspnea,\n             diabetes mellitus, movement disorder and infectious disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732237", 
            "org_study_id": "CR100878", 
            "secondary_id": "42396302EDI1003"
        }, 
        "intervention": [
            {
                "arm_group_label": "JNJ-42396302", 
                "description": "A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.", 
                "intervention_name": "JNJ-42396302", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-42396302"
            }, 
            {
                "arm_group_label": "JNJ-42692507", 
                "description": "A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.", 
                "intervention_name": "JNJ-42692507", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-42692507"
            }, 
            {
                "arm_group_label": "JNJ-53773187", 
                "description": "A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.", 
                "intervention_name": "JNJ-53773187", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-53773187"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy", 
            "JNJ-42396302", 
            "JNJ-42692507", 
            "JNJ-53773187", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Single Dose Study to Investigate the Pharmacokinetics of an Oral Microdose of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Janssen-Cilag International NV", 
            "last_name": "Janssen-Cilag International NV Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Drugs and Health products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma analyte concentration (Cmax) of JNJ-42396302", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Area under the plasma concentration time curve for JNJ-42396302", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-42396302", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Apparent terminal elimination half-life of JNJ-42396302", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Maximum observed plasma analyte concentration (Cmax) of JNJ-53773187", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Area under the plasma concentration time curve for JNJ-53773187", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-53773187", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Apparent terminal elimination half-life of JNJ-53773187", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Maximum observed plasma analyte concentration (Cmax) of JNJ-42692507", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Area under the plasma concentration time curve for JNJ-42692507", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-42692507", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }, 
            {
                "measure": "Apparent terminal elimination half-life of JNJ-42692507", 
                "safety_issue": "No", 
                "time_frame": "10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732237"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "within 7 days after the last dose of the study medication"
        }, 
        "source": "Janssen-Cilag International NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen-Cilag International NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}